Background: Treatment options for patients with platinum-resistant ovarian cancer are
generally palliative in nature and rarely have realistic potential to be curative. Because many …

Epithelial ovarian cancer (EOC) is responsible for more cancer-related deaths than any
other malignancy of the female reproductive system. The standard of care for advanced EOC …

Objective Use of in vitro chemoresponse assays for informing effective treatment selection is
a compelling clinical question and a topic of debate among oncologists. A prospective study …

Individualized therapy has the ability to guide the use of chemotherapy as well as newer
agents. The development of companion diagnostics for drugs used in ovarian cancer has …

In this era of personalized medicine, patients with recurrent ovarian cancer deserve better
than the 25% response rate that is associated with drugs selected based on clinical …

Therapy resistance is a major challenge in the management of ovarian cancer (OC).
Advances in detection and new technology validation have led to the emergence of …

Patients presenting with stage 4 ovarian carcinoma, including low-grade serous disease,
have a poor prognosis. Although platinum-based therapies can offer some response, these …

The objective of this review is to summarize recent scientific and medical literature regarding
chemoresponse assays or chemotherapy sensitivity and resistance assays (CSRAs) …

Purpose With this study, we intended to construct a personalized drug-screening system for
platinum-resistant ovarian cancer patients by consulting a patient's medical history, data …

Background: Metastatic disease in ovarian cancer is difficult to treat and patients often
exhaust standard-of-care regimens. To get a better understanding of potential treatments …